{"prompt": "['Carbomer and Carboxymethyleellulose', '209510', 'Clinical Protocol V1.0', 'Fetal distress, fetal death, or any congenital abnormality or birth defects', 'Examples of incidents:', 'A subject, user, caregiver, or healthcare professional is injured as a result of a medical', 'device failure or its misuse.', \"A subject's study treatment is interrupted or compromised by a medical device failure.\", 'A misdiagnosis due to medical device failure leads to inappropriate treatment.', \"A subject's health deteriorates due to medical device failure.\", '10.9.2', 'Reporting of Incidents and Malfunctions', 'All incidents must be reported to GSK CH within 24 hours (or sooner if possible) of the', 'investigator or designee becoming aware of the situation.', \"Any medical device incident occurring during the study will be documented in the subject's\", \"medical records, if in accordance with the investigator's normal clinical practice, and on the\", 'appropriate Incident Report Form. In addition, for incidents fulfilling the definition of an AE', '(serious and non-serious), the appropriate AE CRF page and SAE form will be completed and', 'reported as per the AE and SAE reporting sections.', 'The Incident Report Form will be completed as thoroughly as possible and signed by the', 'investigator before transmittal to GSK CH. It is very important that the investigator describes', 'any corrective or remedial actions taken to prevent recurrence of the incident.', 'The completed Incident Report Form should be scanned and emailed to the GSK CH Clinical', 'Operations Safety Reporting email box with the study number and subject number in the subject', 'line of the email as soon as possible, but not more than 24 hours after study site personnel', 'learn of the event. If there is an SAE, the completed SAE form should be sent together with this', 'report form. However, if a copy of the SAE report is sent with this form, this does not replace', 'the procedure to report an SAE. The original Incident Report Form will be retained in the', 'investigator study master file.', 'The GSK CH Study Manager should be notified of the situation by telephone or email.', 'Email the Incident Report Forms to:', 'PPD', 'The GSK CH Study Manager or designee will be responsible for forwarding the Incident Report', 'Form to the Case Management Group, Global Clinical Safety and Pharmacovigilance group', 'mailbox (PPD', '), responsible for the study and other GSK CH personnel as', 'appropriate.', 'The initial report will be followed up with more information as relevant, or as requested by the', 'GSK CH study manager.', 'The investigator will follow the following directions regarding the reporting of a device failure', '(malfunction):', 'Notify GSK CH immediately (by following the process described above).', 'Schedule the subject to return to the site promptly to return the failed device.', 'Record any incidents on the CRF and Incident Report Form following instructions given', 'in the section above.', 'Return the failed device to the Sponsor as soon as possible, including documentation of', 'the details of the failure', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 46 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'All communications regarding a medical device incident should be directed towards the GSK', 'CH study manager. In order to maintain blinding, these communications will not involve the', 'study statistician or the study clinical research scientist. The study manager will assess if follow', 'up action is required, and if necessary utilize study-independent scientists who will not be', 'involved in the analysis and reporting of this study.', '10.9.3 Follow-up of Medical Device Incidents', 'Medical device incidents involving an AE will be followed and reported in the same manner as', 'other AEs. This applies to all subjects, including those who discontinue study product or are', 'withdrawn from the study.', 'The investigator is responsible for ensuring that follow-up includes any supplemental', 'investigations as indicated to elucidate the nature and/or causality of the incident.', 'New or updated information will be recorded on the originally completed Incident Report form', 'with all changes signed and dated by the investigator.', '10.9.4 Regulatory and Ethics Reporting Requirements for Incidents', 'To fulfill regulatory reporting obligations worldwide, the investigator is responsible for the', 'detection and documentation of events meeting the definitions of incident or malfunction that', 'occur during all periods of the study in which the medical device is used.', 'The investigator will promptly report all incidents occurring with any medical device provided', 'for use in the study in order for the Sponsor to fulfill the legal responsibility to notify appropriate', 'regulatory authorities and other entities about certain safety information relating to medical', 'devices being used in clinical studies.', 'The investigator, or responsible person according to local requirements (e.g. the head of the', 'medical institution), will comply with the applicable local regulatory requirements relating to', 'the reporting of incidents to the IRB/IEC.', '11', 'DATA MANAGEMENT', 'As used in this protocol, the term CRF is understood to refer to either a paper form or an', 'electronic data record or both, depending on the data collection method.', 'For this study, subject data will be entered into an electronic CRF (eCRF), using a validated', 'system. Data relating to SAEs, pregnancy and incidents will also be collected on paper forms.', 'The investigator is responsible for verifying that data entries are accurate and correct by', 'physically or electronically signing the CRF.', 'The source documents (e.g. hospital records, clinical and office charts, laboratory notes,', 'memoranda, subject diaries, questionnaires, evaluation checklists, pharmacy dispensing records,', 'recorded data from automated instruments, microfiches, photographic negatives, microfilm or', 'magnetic media, x-rays, subject files and records kept at the pharmacy, at the laboratory and at', 'the medico-technical departments involved in the clinical study) which contain the source of', 'data recorded in the CRF should be specified in Section 8 and 9. The CRF and/or diary can be', 'used as a source document at the discretion of data management.', 'Each subject will be assigned and identified by a unique Screening Subject Number. Any', 'reference made to an individual subject within the study must be done using their unique', 'Screening Subject Number.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 47 of 65']\n\n###\n\n", "completion": "END"}